New efficacy and safety data adds to evidence supporting treatment with afatinib* (GIOTRIF®) in Asian and non-Asian lung cancer patients

28-10-2013 Business Wire HealthComments (0)


Data from two pivotal large-scale Phase III registration studies, LUX-Lung 3 and LUX-Lung 6, showed superior efficacy and a manageable safety profile in both Asian and non-Asian lung cancer patients compared to chemotherapy.2,3 A new analysis of the trials has substantiated the consistent safety profile of afatinib as a first-line treatment in Asian and non-Asian patients with EGFR mutation positive non-small cell lung cancer (NSCLC).1

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top